Antimicrobial Agents and Chemotherapy · 2016 · 51 citations · 40 references
Life SciencesInfectious DiseasesMicrobiologyAntimicrobial ResistanceBacteriologyMedical MicrobiologyAntibacterial ResistanceAntibiotic ResistanceAntibiotic Resistance MechanismsBeta-lactam ResistanceCarbapenem ResistanceResistance EpidemiologyAminoglycoside AntibioticsAminoglycoside-modifying EnzymesAntibiotic-modifying EnzymesExtended-spectrum Beta-lactamase Producing OrganismsExtended-spectrum Beta-lactamase-producing OrganismsExtended-spectrum Beta-lactamasesKlebsiella Pneumoniae CarbapenemaseKlebsiella Pneumoniae Resistance
We compared the in vitro activities of gentamicin (GEN), tobramycin (TOB), amikacin (AMK), and plazomicin (PLZ) against 13 Enterobacter isolates possessing both Klebsiella pneumoniae carbapenemase and extended-spectrum β-lactamase (KPC+/ESBL+) with activity against 8 KPC+/ESBL-, 6 KPC-/ESBL+, and 38 KPC-/ESBL- isolates. The rates of resistance to GEN and TOB were higher for KPC+/ESBL+ (100% for both) than for KPC+/ESBL- (25% and 38%, respectively), KPC-/ESBL+ (50% and 17%, respectively), and KPC-/ESBL- (0% and 3%, respectively) isolates. KPC+/ESBL+ isolates were more likely than others to possess an aminoglycoside-modifying enzyme (AME) (100% versus 38%, 67%, and 5%; P = 0.007, 0.06, and <0.0001, respectively) or multiple AMEs (100% versus 13%, 33%, and 0%, respectively; P < 0.01 for all). KPC+/ESBL+ isolates also had a greater number of AMEs (mean of 4.6 versus 1.5, 0.9, and 0.05, respectively; P < 0.01 for all). GEN and TOB MICs were higher against isolates with >1 AME than with ≤1 AME. The presence of at least 2/3 of KPC, SHV, and TEM predicted the presence of AMEs. PLZ MICs against all isolates were ≤4 μg/ml, regardless of KPC/ESBL pattern or the presence of AMEs. In conclusion, GEN and TOB are limited as treatment options against KPC+ and ESBL+ Enterobacter PLZ may represent a valuable addition to the antimicrobial armamentarium. A full understanding of AMEs and other aminoglycoside resistance mechanisms will allow clinicians to incorporate PLZ rationally into treatment regimens. The development of molecular assays that accurately and rapidly predict antimicrobial responses among KPC- and ESBL-producing Enterobacter spp. should be a top research priority.
40
Alicia Hidrón, Jonathan R. Edwards, Jean B. Patel et al. · Infection Control and Hospital Epidemiology · 2008 · 3.8K citations
Dawn Sievert, Philip Ricks, Jonathan R. Edwards et al. · Infection Control and Hospital Epidemiology · 2012 · 1.6K citations
Veterinary Medicine, Infectious Disease Control, Infectious Diseases +17